title: A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy.
abstract: African Americans (AA) have traditionally been thought to have higher immunologic risk than Caucasians (CA) for rejection and allograft loss. The impact of ethnicity on the outcome of simultaneous pancreas-kidney (SPK) transplant with basiliximab induction has not been reported. In this study, we retrospectively analyze the long-term results of 36 AA and 55 CA recipients of primary SPK. The actual patient survival rates of AA and CA groups were 91.7% vs. 90.1% at 1 year, 93.3% vs. 88.1% at 3 years, and 94.4% vs. 83.3% at 5 years. The actual kidney survival of AA and CA were 91.7% vs. 89.1% at 1 year, 90% vs. 81% at 3 years, and 83.3% vs. 75% at 5 years. The actual pancreas survival of AA and CA were 88.9% vs. 85.5% at 1 year, 83.3% vs. 78.6% at 3 years and 72.2% vs. 70.8% at 5 years. Death-censored analyses also found no difference in pancreas and kidney graft survival rates over 5 years. Higher rejection rate, but the same low CMV infection, and comparable quality of graft function were noted in AA group. AA may not have worse long-term outcomes than CA recipients of SPK with basiliximab induction and tacrolimus (TAC), mycophenolate acid (MFA) and steroid maintenance immunotherapy.
authors.affiliation: Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA. rzhang@tulane.edu
authors.forename: R
authors.initials: R
authors.lastname: Zhang
authors.forename: S
authors.initials: S
authors.lastname: Florman
authors.forename: S
authors.initials: S
authors.lastname: Devidoss
authors.forename: A
authors.initials: A
authors.lastname: Zarifian
authors.forename: C L
authors.initials: CL
authors.lastname: Yau
authors.forename: A
authors.initials: A
authors.lastname: Paramesh
authors.forename: M
authors.initials: M
authors.lastname: Killackey
authors.forename: B
authors.initials: B
authors.lastname: Alper
authors.forename: V
authors.initials: V
authors.lastname: Fonseca
authors.forename: D
authors.initials: D
authors.lastname: Slakey
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D044383:Black People / Q000706:statistics & numerical data*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008145:Louisiana; D016035:Pancreas Transplantation / Q000276:immunology* / Q000401:mortality; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D017741:Survivors; D013997:Time Factors; D044465:White People / Q000706:statistics & numerical data*; D001741:Black or African American
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab